Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination

Nature Reviews Clinical Oncology

Volumn 7, Issue 10, 2010, Pages 600-603

  Bocchia, Monica ^a   Defina, Marzia ^a   Aprile, Lara ^a   Ippoliti, Micaela ^a   Crupi, Rosaria ^a   Rondoni, Michela ^a   Gozzetti, Alessandro ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

25 MER B2A2 BREAKPOINT DERIVED PEPTIDE VACCINE; ALPHA INTERFERON; BCR ABL PROTEIN; BCR ABL1 PROTEIN; CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CD4+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DELAYED HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; LEUKOCYTOSIS; LYMPHOCYTE PROLIFERATION; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY;

CANCER VACCINES; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; VACCINATION;

EID: 77957560308     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.141     Document Type: Article

References (17)

1. Hehlmann, R., Hochhaus, A. & Baccarani, M. Chronic myeloid leukaemia. Lancet 370, 342-350 (2007).
2. Muller, M. C. et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22, 96-102 (2008).
3. Kantarjian, H., Shifter, C., Jones, D. & Cortes, J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111, 1774-1780 (2008).
4. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2007).
5. Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat. Rev. Clin. Oncol. 6, 535-543 (2009).
6. De Lavallade, H. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol. 26, 3358-3363 (2008).
7. Bonifazi, F. et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98, 3074-3081 (2001).
8. Beelen, D. W. & Schaefer, U. W. Allogeneic stem cell transplants in chronic myeloid leukemia. Ann. Hematol. 81 (Suppl. 2), S45-S46 (2002).
9. Hochhaus, A. et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054-1061 (2009).
10. Rousselot, P et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58-60 (2007).
11. Bocchia, M. et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662 (2005).
12. Rojas, J. M., Knight, K., Wang, L. & Clark, R. E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21, 2287-2295 (2007).
13. Jain, N. et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115, 3924-3934 (2009).
14. Bocchia, M. et al. BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party Trial. ASH Annual Meeting Abstracts 114, 648 (2009).
15. Radich, J. P. How I monitor residual disease in chronic myeloid leukemia. Blood 114, 3376-3381 (2009).
16. Burchert, A. et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 28, 1429-1435 (2010).
17. +CTLs) in chronic myeloid leukemia patients: new insights about peptide vaccine-mediated antitumor response. ASH Annual Meeting Abstracts 112, 3209 (2008).